Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 2
2009 3
2010 2
2012 1
2013 1
2014 2
2015 1
2016 4
2017 2
2018 2
2019 7
2020 2
2021 4
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study).
Nishio K, Sakai K, Nishio M, Seto T, Visseren-Grul C, Carlsen M, Matsui T, Enatsu S, Nakagawa K. Nishio K, et al. Among authors: enatsu s. Transl Lung Cancer Res. 2023 Aug 30;12(8):1702-1716. doi: 10.21037/tlcr-22-736. Epub 2023 Aug 10. Transl Lung Cancer Res. 2023. PMID: 37691865 Free PMC article.
RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC.
Nishio M, Nishio K, Reck M, Garon EB, Imamura F, Kawaguchi T, Yamaguchi H, Ikeda S, Hirano K, Visseren-Grul C, Ceccarelli M, Wijayawardana SR, Zimmermann A, Matsui T, Enatsu S, Nakagawa K. Nishio M, et al. Among authors: enatsu s. JTO Clin Res Rep. 2022 Feb 26;3(4):100303. doi: 10.1016/j.jtocrr.2022.100303. eCollection 2022 Apr. JTO Clin Res Rep. 2022. PMID: 35369607 Free PMC article.
Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset.
Nishio K, Seto T, Nishio M, Reck M, Garon EB, Sakai K, Goto K, Kato T, Nakanishi Y, Takahashi T, Yamamoto N, Kiura K, Ohe Y, Tamura T, Visseren-Grul C, Frimodt-Moller B, Hozak RR, Wijayawardana SR, Zimmermann A, Homma G, Enatsu S, Nakagawa K. Nishio K, et al. Among authors: enatsu s. JTO Clin Res Rep. 2021 Apr 16;2(6):100171. doi: 10.1016/j.jtocrr.2021.100171. eCollection 2021 Jun. JTO Clin Res Rep. 2021. PMID: 34590023 Free PMC article.
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Toi M, Inoue K, Masuda N, Iwata H, Sohn J, Hae Park I, Im SA, Chen SC, Enatsu S, Turner PK, André VAM, Hardebeck MC, Sakaguchi S, Goetz MP, Sledge GW Jr. Toi M, et al. Among authors: enatsu s. Cancer Sci. 2021 Jun;112(6):2381-2392. doi: 10.1111/cas.14877. Epub 2021 May 1. Cancer Sci. 2021. PMID: 33686753 Free PMC article. Clinical Trial.
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
Nishio M, Seto T, Reck M, Garon EB, Chiu CH, Yoh K, Imamura F, Park K, Shih JY, Visseren-Grul C, Frimodt-Moller B, Zimmermann A, Homma G, Enatsu S, Nakagawa K; RELAY Study Investigators. Nishio M, et al. Among authors: enatsu s. Cancer Sci. 2020 Dec;111(12):4510-4525. doi: 10.1111/cas.14655. Epub 2020 Oct 14. Cancer Sci. 2020. PMID: 32954593 Free PMC article. Clinical Trial.
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis.
Yang JC, Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Hozak RR, Nguyen TS, Zhang WL, Enatsu S, Puri T, Orlando M. Yang JC, et al. Among authors: enatsu s. J Thorac Oncol. 2020 Jan;15(1):91-100. doi: 10.1016/j.jtho.2019.09.008. Epub 2019 Oct 9. J Thorac Oncol. 2020. PMID: 31605797 Free article. Clinical Trial.
34 results